Evidence map›Paper›PMID 28191018›Full record

ArticleStem cells international2017

Thymosin

Tilman Ziegler, Rabea Hinkel, Andrea Stöhr, Thomas Eschenhagen, Karl-Ludwig Laugwitz, Ferdinand le Noble, Robert David, Arne Hansen, Christian Kupatt

Open access · goldAbstract read
In one paragraph

Article in Stem cells international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Evaluating Novel Targets of Ischemia Reperfusion Injury in Pig Models.International journal of molecular sciences · 2019
    Review
  3. Cardiovascular Gene Therapy: Past, Present, and Future.Molecular therapy : the journal of the American Society of Gene Therapy · 2017
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Tilman ZieglerI. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Munich, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.
Rabea HinkelI. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Munich, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany; Institute for Cardiovascular Prevention, Ludwig Maximilians University, Munich, Germany.
Andrea StöhrInstitut für Experimentelle Pharmakologie und Toxikologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
Thomas EschenhagenInstitut für Experimentelle Pharmakologie und Toxikologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
Karl-Ludwig LaugwitzI. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Munich, Germany.
Ferdinand le NobleKarlsruher Institut für Technologie, Karlsruhe, Germany.
Robert DavidDepartment of Cardiac Surgery, Reference and Translation Center for Cardiac Stem Cell Therapy (RTC), University of Rostock, Rostock, Germany.
Arne HansenInstitut für Experimentelle Pharmakologie und Toxikologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany.
Christian KupattI. Medizinische Klinik und Poliklinik, Klinikum rechts der Isar, Munich, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany.ORCID 0000-0002-3611-1218
TUM Klinikum · DEUniversität Hamburg · DEKarlsruhe Institute of Technology · DEUniversity of Rostock · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Induced pluripotent stem cells (iPSC) constitute a powerful tool to study cardiac physiology and represents a promising treatment strategy to tackle cardiac disease. However, iPSCs remain relatively immature after differentiation. Additionally, engineered heart tissue (EHT) has been investigated as a therapy option in preclinical disease models with promising results, although their vascularization and functionality leave room for improvement. Thymosin

Identifiers

PMID28191018
PMCPMC5278226
OpenAlexW2571847691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.